Literature DB >> 14614024

Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.

Hiroya Kobayashi1, Ryusuke Omiya, Benjamin Sodey, Mitsuru Yanai, Kensuke Oikawa, Keisuke Sato, Shoji Kimura, Satoru Senju, Yasuharu Nishimura, Masatoshi Tateno, Esteban Celis.   

Abstract

PURPOSE: There is growing evidence that CD4(+) helper T lymphocytes (HTLs) play an essential role in the induction and long-term maintenance of antitumor CTL responses. Thus, approaches to develop effective T-cell-based immunotherapy should focus in the stimulation of both CTLs and HTLs reactive against tumor-associated antigens. The present studies were performed with the purpose of identifying HTL epitopes for prostate-specific membrane antigen (PSMA) for the optimization of vaccines for prostate cancer. EXPERIMENTAL
DESIGN: Synthetic peptides from regions of the PSMA sequence that were predicted to serve as HTL epitopes were prepared with use of computer-based algorithms and tested for their capacity to trigger in vitro HTL responses in lymphocytes from normal volunteers.
RESULTS: Our results show that 4 peptides from PSMA were effective in eliciting HTL responses. Moreover, HTL reactive to 3 of the 4 peptides were capable of reacting with naturally processed antigen in the form of freeze/thaw lysates or apoptotic cells produced from PSMA-positive LNCaP tumor cell lines.
CONCLUSIONS: Human HTLs are capable of effectively recognizing epitopes derived from PSMA. The information presented here should facilitate the design of improved vaccination strategies for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614024

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.

Authors:  Polly Gregor; Q Daisy Huang; Humilidad F Gallardo; Teresa S Rasalan; Michael J Morris
Journal:  Clin Genitourin Cancer       Date:  2012-01-27       Impact factor: 2.872

2.  In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.

Authors:  Hiroya Kobayashi; Toshihiro Ngato; Keisuke Sato; Naoko Aoki; Shoji Kimura; Yuetsu Tanaka; Hitoshi Aizawa; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

3.  Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.

Authors:  Hiroya Kobayashi; Toshihiro Nagato; Kensuke Oikawa; Keisuke Sato; Shoji Kimura; Naoko Aoki; Ryusuke Omiya; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 4.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

Review 5.  CAR-T cell therapy: a potential new strategy against prostate cancer.

Authors:  Giuseppe Schepisi; Maria Concetta Cursano; Chiara Casadei; Cecilia Menna; Amelia Altavilla; Cristian Lolli; Claudio Cerchione; Giovanni Paganelli; Daniele Santini; Giuseppe Tonini; Giovanni Martinelli; Ugo De Giorgi
Journal:  J Immunother Cancer       Date:  2019-10-16       Impact factor: 13.751

Review 6.  Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.

Authors:  Young Dong Yu; Tae Jin Kim
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

7.  Tumor-associated antigens for specific immunotherapy of prostate cancer.

Authors:  Andrea Kiessling; Rebekka Wehner; Susanne Füssel; Michael Bachmann; Manfred P Wirth; Marc Schmitz
Journal:  Cancers (Basel)       Date:  2012-02-22       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.